Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Yamane, Kazuhiko ^a   Indalao, Irene L ^a   Chida, Junji ^a   Yamamoto, Yoshikazu ^b   Hanawa, Masaaki ^b   Kido, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; DIISOPROPYLAMINE DICHLOROACETATE; GLUCOSE; LACTIC ACID; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE 4; TRYPSIN; MESSENGER RNA; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRUVIC ACID; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE STORM; DISEASE SEVERITY; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART; INFLUENZA; LACTATE BLOOD LEVEL; LIPID METABOLISM; LIVER; LUNG; METABOLIC DISORDER; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SKELETAL MUSCLE; UPREGULATION; VIRUS REPLICATION; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; GENETICS; INFLUENZA A VIRUS (H1N1); METABOLIC DISEASES; METABOLISM; ORTHOMYXOVIRUS INFECTION; OXIDATION REDUCTION REACTION; PATHOGENICITY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE; INFLUENZA A VIRUS, H1N1 SUBTYPE; LIPID METABOLISM; METABOLIC DISEASES; MICE; MICE, INBRED C57BL; MULTIPLE ORGAN FAILURE; ORTHOMYXOVIRIDAE INFECTIONS; OXIDATION-REDUCTION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRUVIC ACID; QUATERNARY AMMONIUM COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84901477996     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098032     Document Type: Article

References (62)

1. Lipatov MS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, et al. (2004) Influenza: emergence and control. J Virol 78: 8951-8959. (Pubitemid 39096507)
2. Kim HW, Brandt CD, Arrobio JO, Murphy B, Chanock RM, et al. (1979) Influenza A and B virus infection in infants and young children during the years 1957-1976. Am J Epidemiol 109: 464-479. (Pubitemid 10201097)
3. Chowell G, Echevarria-Zuno S, Viboud C, Simonsen L, Miller MA, et al. (2012) Epidemiological Characteristics and Underlying Risk Factors for Mortality during the Autumn 2009 Pandemic Wave in Mexico. PLoS One 7: e41069. Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0041069.
4. Delorme L, Middleton PL (1979) Influenza A virus associated with acute encephalopathy. Am J Dis Child 133: 822-824. (Pubitemid 10094149)
5. Yao D, Mizuguchi H, Yamaguchi M, Yamada H, Chida J, et al. (2008) Thermal instability of compound variants of carnitine palmitoyltransferase II and impaired mitochondrial fuel utilization in influenza-associated encephalopathy. Hum Mutat 29: 718-727. (Pubitemid 351614597)
6. Perkins LE, Swayne DE (2001) Pathobiology of A/chicken/Hong Kong/220/97 (H5N1) avian influenza virus in seven gallinaceous species. Vet Pathol 38: 149-164. (Pubitemid 33621690)
7. Wang S, Le TQ, Kurihara N, Chida J, Cisse Y, et al. (2010) Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis 202: 991-1001.
8. Spraque AH, Khalil RA (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 78: 539-552.
9. Mariappan N, Elks CM, Fink B, Francis J (2009) TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction. Free Radic Biol Med 46: 462-470.
10. Mizuguchi M, Yamanouchi H, Ichiyama T, Shiomi M (2007) Acute encephalopathy associated with influenza and other viral infections. Acta Neurol Scand Suppl 186: 45-56. (Pubitemid 46376171)
11. Denker BM, Nigam SK (1998) Molecular structure and assembly of the tight junction. Am J Physiol 274: F1-F9.
12. Kido H, Okumura Y, Takahashi E, Pan HY, Wang S, et al. (2012) Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure. Biochim Biophys Acta 1824: 186-194.
13. Pan HY, Yamada H, Chida J, Wang S, Yano M, et al. (2011) Up-regulation of ectopic trypsins in the myocardium by influenza A virus infection triggers acute myocarditis. Cardiovasc Res 58: 19-28.
14. Pan HY, Yano M, Kido H (2011) Effects of inhibitors of Toll-like receptors, protease-activated receptor-2 signalings and trypsin on influenza A virus replication and upregulation of cellular factors in cardiomyocytes. J Med Invest 58: 19-28.
15. Chen Y, Mizuguchi H, Yao D, Ide M, Kuroda Y, et al. (2005) Thermolabile phenotype of carnitine palmitoyltransferase II variations as a predisposing factor for influenza-associated encephalopathy. FEBS Lett 579: 2040-2044. (Pubitemid 40469667)
16. Yao D, Yao M, Yamaguchi M, Chida J, Kido H (2011) Characterization of compound missense mutation and deletion of carnitine palmitoyltransferase II in a patient with adenovirus-associated encephalopathy. J Med Invest 58: 210-218.
17. Sugden MC, Holness MJ (2003) Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 284: E855-E862. (Pubitemid 36444020)
18. Harris RA, Bowker-Kinley MM, Huang B, Wu P (2002) Regulation of the activity of the pyruvate dehydrogenase complex. Adv Enzyme Regul 42: 249-259. (Pubitemid 35033542)
19. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM (1998) Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 329: 191-196. (Pubitemid 28022308)
20. Jeong JY, Jeoung NH, Park KG, Lee IK (2012) Transcriptional regulation of pyruvate dehydrogenase kinase. Diabetes Metab J 36: 328-335.
21. Herbert V (1979) Pangamic acid ("vitamin B15"). Am J Clin Nutr 32: 1534-1540.
22. Naito E, Kuroda Y, Toshima K, Takeda E, Saijo T, et al. (1989) Effect of sodium dichloroacetate on human pyruvate metabolism. Brain Dev 11: 195-197. (Pubitemid 19149740)
23. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, et al. (2006) Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117: 1519-1531. (Pubitemid 46071378)
24. Chida J, Yamane K, Takei T, Kido H (2012) An efficient extraction method for quantitation of adenosine triphosphate in mammalian tissues and cells. Anal Chim Acta 727: 8-12.
25. Chida J, Ono R, Yamane K, Hiyoshi M, Nishimura M, et al. (2013) Blood lactate/ATP ratio, as an alarm index and real-time biomarker in critical illness. PLoS One 8: e60561.
26. Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, et al. (2013) Activitybased kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 18: 110-122.
27. Ushikai M, Horiuchi M, Kobayashi K, Matuda S, Inui A, et al. (2011) Induction of PDK4 in the heart muscle of JVS mice, an animal model of systemic carnitine deficiency, does not appear to reduce glucose utilization by the heart. Mol Genet Metab 102: 349-355.
28. Kato M, Li J, Chuang JL, Chuang DT (2007) Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure 15: 992-1004. (Pubitemid 47212754)
29. Bersin RM, Stacpoole PW (1997) Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J 134: 841-855. (Pubitemid 27522989)
30. Hardaway AL, Podgorski I (2013) IL-1b, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem 5: 1089-1108.
31. Lee H, Lee IS, Choue R (2013) Obesity, inflammation and diet. Pediatr Gastroenterol Hepatol Nutr 16: 143-152.
32. Close TE, Cepinskas G, Omatsu T, Rose KL, Summers K, et al. (2013) Diabetic ketoacidosis elicits systemic inflammation associated with cerebrovascular endothelial cell dysfunction. Microcirculation 20: 534-543.
33. Moseley CE, Webster RG, Aldridge JR (2010) Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respi Viruses 4: 307-311.
34. Fedson DS (2009) Confronting the next influenza pandemic with antiinflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 3: 129-142.
35. Yang B, Yao D, Ohuchi M, Ide M, Yano M, et al. (2002) Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J 19: 952-958. (Pubitemid 34567912)
36. Yamada H, Le QT, Kousaka A, Higashi Y, Tsukane M, et al. (2006) Sendai virus infection up-regulates trypsin I and matrix metalloproteinase-9, triggering viral multiplication and matrix degradation in rat lungs and lung L2 cells. Arch Virol 151: 2529-2537. (Pubitemid 44819347)
37. Towatari T, Ide M, Ohba K, Chiba Y, Murakami M, et al. (2002) Identification of ectopic anionic trypsin I in rat lungs potentiating pneumotropic virus infectivity and increased enzyme level after virus infection. Eur J Biochem 269: 2613-2621. (Pubitemid 34539291)
38. Le TQ, Kawachi M, Yamada H, Shiota M, Okumura Y, et al. (2006) Identification of trypsin I as a candidate for influenza A virus and Sendai virus envelope glycoprotein processing protease in rat brain. Biol Chem 387: 467-475.
39. Basler CF (2007) Influenza viruses: basic biology and potential drug targets. Infect Disord Drug Targets 7: 282-293.
40. Dagher Z, Ruderman N, Tornheim K, Ido Y (2001) Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Circ Res 88: 1276-1282. (Pubitemid 32587844)
41. Oldendorf WH, Cornford ME, Brown WJ (1977) The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1: 409-417.
42. Plateel M, Dehouck MP, Torpier G, Cecchelli R, Teissier E (1995) Hypoxia increases the susceptibility to oxidant stress and the permeability of the bloodbrain barrier endothelial cell monolayer. J Neurochem 65: 2138-2145.
43. Witt KA, Mark KS, Hom S, Davis TP (2003) Effects of hypoxia-reoxygenation on rat blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 285: H2820-H2831. (Pubitemid 37443103)
44. Yao M, Yao D, Yamaguchi M, Chida J, Yao D, et al. (2011) Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy. Mol Genet Metab 104: 265-272.
45. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, et al. (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142: 1269-1277. (Pubitemid 32202838)
46. Gallagher D, Belmonte D, Deurenberg P, Wang Z, Krasnow N, et al. (1998) Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol 275: E249-E258.
47. Kim YD, Kim YH, Tadi S, Yu JH, Jeoung NH, et al. (2012) Metformin inhibits growth hormone-mediated hepatic PDK4 gene expression through induction of orphan nuclear receptor small heterodimer partner. Diabetes 61: 2484-2494.
48. McAinch AJ, Cameron-Smith D (2009) Adiponectin decreases pyruvate dehydrogenase kinase 4 gene expression in obese- and diabetic-derived myotubes. Diabetes Obes Metab 11: 721-728.
49. da Rocha Junior LF, Dantas AT, Duarte AL, de Melo Rego MJ, Pitta Ida R, et al. (2013) PPAR c agonists in adaptive immunity: what do immune disorders and their models have to tell us? PPAR Res 2013:519724.
50. Nakamura MT, Yudell BE, Loor JJ (2014) Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res 53: 124-144.
51. Kelly DP (2003) PPARs of the heart: three is a crowd. Circ Res 92: 482-484.
52. Planavila A, Sa'nchez RM, Merlos M, Laguna JC, Va'zquez-Carrera M (2005) Atorvastatin prevents peroxisome proliferator-activated receptor c coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells. Biochim Biophys Acta 1736: 120-127. (Pubitemid 41262569)
53. West AP, Shadel GS, Ghosh S (2011) Mitochondria in innate immune responses. Nat Rev Immunol 11: 389-402.
54. Koshiba T (2013) Mitochondrial-mediated antiviral immunity. Biochim Biophys Acta 1833: 225-232.
55. Hunt JM, Tuder R (2012) Alpha 1 anti-trypsin: one protein, many functions. Curr Mol Med 12: 827-835.
56. Whitehouse S, Cooper RH, Randle PJ (1974) Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 141: 761-774.
57. Henderson GN, Yan Z, James MO, Davydova N, Stacpooles PW (1997) Kinetics and metabolism of chloral hydrate in children: identification of dichloroacetate as a metabolite. Biochem Biophys Res Commun 235: 695-698. (Pubitemid 27326545)
58. Stacpoole PW (1989) The pharmacology of dichloroacetate. Metabolism 38: 1124-1144.
59. Sutendra G, Michelakis ED (2013) Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol 3: 38.
60. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, et al. (2006) Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66: 324-330. (Pubitemid 43739931)
61. Stacpoole PW, Nagaraja NV, Hutson AD (2003) Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 43: 683-691. (Pubitemid 36759145)
62. Lu LG, Zeng MD, Mao YM, Chen CW, Fu QC, et al. (2005) Diisopropylamine dichloroacetate in the treatment of nonalcoholic fatty liver disease: a multicenter random double-blind controlled trial. Zhonghua Gan Zang Bing Za Zhi 13: 92-95.